Journal article
Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study
S Stilgenbauer, B Eichhorst, J Schetelig, S Coutre, JF Seymour, T Munir, SD Puvvada, CM Wendtner, AW Roberts, W Jurczak, SP Mulligan, S Böttcher, M Mobasher, M Zhu, M Desai, B Chyla, M Verdugo, SH Enschede, E Cerri, R Humerickhouse Show all
Lancet Oncology | ELSEVIER SCIENCE INC | Published : 2016
Abstract
Background Deletion of chromosome 17p (del[17p]) in patients with chronic lymphocytic leukaemia confers very poor prognosis when treated with standard chemo-immunotherapy. Venetoclax is an oral small-molecule BCL2 inhibitor that induces chronic lymphocytic leukaemia cell apoptosis. In a previous first-in-human study of venetoclax, 77% of patients with relapsed or refractory chronic lymphocytic leukaemia achieved an overall response. Here we aimed to assess the activity and safety of venetoclax monotherapy in patients with relapsed or refractory del(17p) chronic lymphocytic leukaemia. Methods In this phase 2, single-arm, multicentre study, we recruited patients aged 18 years and older with de..
View full abstractGrants
Awarded by National Cancer Institute
Funding Acknowledgements
AbbVie and Genentech/Roche provided financial support for the study and participated in the design, study conduct, analysis, and interpretation of data as well as the writing, review, and approval of the manuscript. Venetoclax is being developed in a collaboration between AbbVie and Genentech. We thank the patients who participated in this trial and their families; the investigators, study coordinators, and support staff at the clinical sites; AbbVie and Genentech venetoclax team members; Jaimee Glasgow for medical writing support, Joseph Beason and Jingwen Jia for data programming support, Jennifer Arzt and Mia Poteracki for clinical trial operational support, and Andrew Roberts for data review support (all employees of AbbVie).